About MicuRx Pharmaceuticals
MicuRx Pharmaceuticals is a company based in Foster City (United States) founded in 2007 by Zhengyu Yuan and Mikhail F Gordeev. MicuRx Pharmaceuticals has raised $389.28 million across 10 funding rounds from investors including Korea Investment Holdings, CARB-X and Legend Capital. The company has 4 employees. MicuRx Pharmaceuticals operates in a competitive market with competitors including Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others.
- Headquarter Foster City, United States
- Employees 4
- Founders Zhengyu Yuan, Mikhail F Gordeev
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website micurx.com
- Legal Name Micurx Pharmaceuticals
- Total Equity Funding$389.28M (USD)
in 10 rounds
- Latest Funding Round$106.93M (USD), Series E
Dec 2020
- InvestorsKorea Investment Holdings
& 9 more
- Employee Count4
Funding Insights of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has successfully raised a total of $389.28M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $106.93 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $389.28M
- Total Rounds 10
- Last Round Series E — $106.93M
- First Round $10M
(Jun 2007)
- Investors Count 10
All 10 funding rounds of MicuRx Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $106.93M | Series E | – | Legend Capital | |
| Dec 2020 | $107.07M | Series E | – | – | |
| Aug 2020 | $42.98M | Series D | – | – | |
| Mar 2018 | $5.2M | Series D | – | – | |
| Dec 2017 | $15.11M | Series D | – | BioVeda China Fund | – |
| Sep 2016 | $55M | Series C | – | – | |
| Aug 2013 | $25M | Series B | – | – | |
| Oct 2012 | $12M | Series A | – | – | – |
| Jul 2007 | $10M | Series A | – | – | – |
| Jun 2007 | $10M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in MicuRx Pharmaceuticals
MicuRx Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Korea Investment Holdings, CARB-X and Legend Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture Capital firm focused on multiple sectors | – | legendcapital.com.cn | Haidian, China | |
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
AI solutions are provided for industrial monitoring and efficiency. | – | founderhf.com | - | |
VC firm funding companies in China and the US | – | bvcf.com | Huangpu, China | |
- | – | bjdeliancap.com | - | |
- | – | dpbioventures.com | - | |
Private equity investment firm focused on multiple sectors | – | huagaicapital.com | Dongguan, China | |
Operates as an investment advisory firm providing expert guidance. | 2010 | yingkepe.com | Fuzhou, China | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
VC and private equity investments are made in China-US companies. | – | morningside.com.cn | Shanghai, China |
Investor details for MicuRx Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MicuRx Pharmaceuticals
11 people are tracked at MicuRx Pharmaceuticals (9 in leadership, 2 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Zhengyu Yuan | Co-Founder & CEO | Leadership |
Mikhail F Gordeev | Co-Founder | Leadership |
Jinqian Liu | Head of Chemistry | Leadership |
Jerry Li | Chief Financial Officer, Director & SVP | Leadership |
Xinghai Wang | Chief Technology Officer & SVP | Leadership |
Hong Yuan | Chief Clinical Officer, Director & Deputy General Manager | Leadership |
Regis A. Vilchez | Chief Medical Officer | Leadership |
Tao Chen | Medical Director | Leadership |
Lu Lu | Senior Director Of Business Development | Leadership |
Leisa Dennehy | Commercial & Corporate Development | Team |
Zhuoying Chen | Financial Controller | Team |
Complete people profiles for MicuRx Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MicuRx Pharmaceuticals
3 dated milestones of MicuRx Pharmaceuticals across 13 years, from founding to its latest funding, stage changes and deals.
- Founded MicuRx Pharmaceuticals is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series E, of $106.9M.
Competitors of MicuRx Pharmaceuticals
MicuRx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Paratek Pharma, Spero Therapeutics, DermBiont and Cempra, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials | |
| bugworksresearch.com | 2014 | Saratoga, United States | $42.89M | 31 | Drugs for antibiotic-resistant infections and cancer are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. |
Detailed competitors of MicuRx Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MicuRx Pharmaceuticals
The website of MicuRx Pharmaceuticals (micurx.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 344.4% vs previous month
Latest news on Micurx Pharmaceuticals
Complete news archive for MicuRx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to MicuRx Pharmaceuticals
10 companies that operate in the same segment as MicuRx Pharmaceuticals (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MicuRx Pharmaceuticals
MicuRx Pharmaceuticals was founded in 2007.
MicuRx Pharmaceuticals is headquartered in Foster City, United States. It is registered at Foster City, California, United States.
Zhengyu Yuan is the current CEO of MicuRx Pharmaceuticals. They have also founded this company.
MicuRx Pharmaceuticals is a funded company, having raised a total of $389.28M across 10 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 2007.
MicuRx Pharmaceuticals has 4 employees.
MicuRx Pharmaceuticals develops antibiotics against multidrug-resistant (MDR) superbug infections. It is involved in the development of a portfolio that comprises a pipeline of antimicrobial agents to treat gram-positive bacteria, gram-negative bacteria, and fungal infections. Products include MRX-I, an oxazolidinone antibiotic for treating methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci infections which is in phase 3 of the clinical trial; and MRX-II, an oxazolidinone antibiotic for treating hospital-acquired infections. Other candidates are MRX-4 and MRX-8 which are effective against gram-positive and gram-negative bacteria are in phase 2 and 1 of the clinical trial.
MicuRx Pharmaceuticals's top competitors include Spero Therapeutics, Vedanta Biosciences and Paratek Pharma.
MicuRx Pharmaceuticals has 10 investors. Key investors include Korea Investment Holdings, CARB-X, Legend Capital, Yingke Capital, and AI PRO.
MicuRx Pharmaceuticals operates through Micurx Pharmaceuticals.